Data from University of Pittsburgh Advance Knowledge in Cancer Gene Therapy (Delivery of Parp Inhibitors Through 2hg-incorporated Liposomes for Synergistically Targeting Dna Repair In Cancer).

Researchers at the University of Pittsburgh have developed a liposomal formulation for delivering PARP inhibitors (PARPi) and 2-hydroxyglutarate (2HG) to target DNA repair in cancer cells. This approach aims to enhance the effectiveness of PARPi in both HR-deficient and HR-proficient tumors by synergistically enhancing DNA repair defects. The study also found that the combination of veliparib and 2HG via liposomal co-delivery can activate the STING pathway and downregulate PD-L1 expression, potentially augmenting the function of cytotoxic T cells. The research was supported by the National Institutes of Health (NIH) and has been peer-reviewed. [Extracted from the article]